Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
- Conditions
- Glioblastoma Multiforme (GBM)
- Registration Number
- NCT06939400
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Brief Summary
GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.
-
Photosensitizer allergy.
-
Severe coagulation disorder.
-
Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.
- Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.
-
-
Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants with Treatment of Surgical combination Photodyanmic therapy From June 2025 to June 2027
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, Zhejiang, China